Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Period	fcf
2015-12-31	-$17.99M
2016-12-31	-$25.35M
2017-12-31	-$28.44M
2018-12-31	-$48.66M
2019-12-31	-$54.76M
2020-12-31	-$72.00M
2021-12-31	-$105.70M
2022-12-31	-$110.69M
2023-12-31	-$124.82M
2024-12-31	$134.32M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KURA	$8.80	-0.23%	0.67M
3
4
5

Kura Oncology Inc. (KURA) Free Cash Flow

Free Cash Flow Data

Get Kura Oncology Inc. Data in Excel

More KURA Financial Data